Brainstorm Cell Therapeutics (NASDAQ:BCLI) Posts Quarterly Earnings Results, Hits Expectations

Brainstorm Cell Therapeutics (NASDAQ:BCLI) issued its earnings results on Wednesday. The biotechnology company reported ($0.04) EPS for the quarter, meeting analysts’ consensus estimates of ($0.04), Zacks reports. During the same quarter in the previous year, the company posted ($0.27) earnings per share.

Brainstorm Cell Therapeutics Stock Up 2.7 %

Shares of NASDAQ BCLI traded up $0.01 during trading on Thursday, reaching $0.31. 318,646 shares of the stock were exchanged, compared to its average volume of 806,977. The company has a market capitalization of $21.95 million, a price-to-earnings ratio of -0.98 and a beta of 0.37. The business’s 50-day moving average price is $0.36 and its 200 day moving average price is $0.43. Brainstorm Cell Therapeutics has a twelve month low of $0.13 and a twelve month high of $1.81.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Maxim Group upgraded Brainstorm Cell Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 price target for the company in a report on Thursday, July 11th. StockNews.com started coverage on Brainstorm Cell Therapeutics in a research report on Wednesday. They issued a “hold” rating for the company.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.